232 related articles for article (PubMed ID: 19080757)
21. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.
Hino H; Araki K; Uyama E; Takeya M; Araki M; Yoshinobu K; Miike K; Kawazoe Y; Maeda Y; Uchino M; Yamamura K
Hum Mol Genet; 2004 Jan; 13(2):181-90. PubMed ID: 14645203
[TBL] [Abstract][Full Text] [Related]
22. Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.
Rivera D; Mejia-Lopez H; Pompa-Mera EN; Villanueva-Mendoza C; Nava-Castañeda A; Garnica-Hayashi L; Cuevas-Covarrubias S; Zenteno JC
Br J Ophthalmol; 2008 Jul; 92(7):998-1002. PubMed ID: 18577654
[TBL] [Abstract][Full Text] [Related]
23. Oculopharyngeal Muscular Dystrophy and Inherited Retinal Dystrophy in Bukhara Jews Due to Linked Mutations in the PABPN1 and NRL Genes.
Braverman I; Blumen SC; Newman H; Rizel L; Khayat M; Hanna R; St Guily JL; Tiosano B; Ben-Yosef T
Genet Test Mol Biomarkers; 2017 Jul; 21(7):450-453. PubMed ID: 28590779
[TBL] [Abstract][Full Text] [Related]
24. Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy.
Mankodi A; Wheeler TM; Shetty R; Salceies KM; Becher MW; Thornton CA
Neurobiol Dis; 2012 Jan; 45(1):539-46. PubMed ID: 21964252
[TBL] [Abstract][Full Text] [Related]
25. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
[TBL] [Abstract][Full Text] [Related]
26. Oculopharyngeal muscular dystrophy --an under-diagnosed disease in China? Report a China-born Chinese with PABPN1 mutation and epidemiology review of the literature.
Chien YY
J Formos Med Assoc; 2012 Jul; 111(7):397-402. PubMed ID: 22817818
[TBL] [Abstract][Full Text] [Related]
27. Proteomic analysis reveals that wildtype and alanine-expanded nuclear poly(A)-binding protein exhibit differential interactions in skeletal muscle.
Banerjee A; Phillips BL; Deng Q; Seyfried NT; Pavlath GK; Vest KE; Corbett AH
J Biol Chem; 2019 May; 294(18):7360-7376. PubMed ID: 30837270
[TBL] [Abstract][Full Text] [Related]
28. Oculopharyngeal muscular dystrophy: phenotypic and genotypic characteristics of 9 Polish patients.
Nadaj-Pakleza A; Richard P; Lusakowska A; Gajewska J; Jamrozik Z; Kostera-Pruszczyk A; Kwieciński H; Kamińska A
Neurol Neurochir Pol; 2009; 43(2):113-20. PubMed ID: 19484687
[TBL] [Abstract][Full Text] [Related]
29. Dropped-head in recessive oculopharyngeal muscular dystrophy.
Garibaldi M; Pennisi EM; Bruttini M; Bizzarri V; Bucci E; Morino S; Talerico C; Stoppacciaro A; Renieri A; Antonini G
Neuromuscul Disord; 2015 Nov; 25(11):869-72. PubMed ID: 26494409
[TBL] [Abstract][Full Text] [Related]
30. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
[TBL] [Abstract][Full Text] [Related]
31. Animal model of oculopharyngeal muscular dystrophy.
Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
[TBL] [Abstract][Full Text] [Related]
32. A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G > C; p.Gly12Ala point mutation.
Nishii YS; Noto YI; Yasuda R; Kitaoji T; Ashida S; Tanaka E; Minami N; Nishino I; Mizuno T
BMC Neurol; 2021 Jul; 21(1):265. PubMed ID: 34225694
[TBL] [Abstract][Full Text] [Related]
33. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Rose C; Sarkar S; Rubinsztein DC
Sci Transl Med; 2010 Jun; 2(34):34ra40. PubMed ID: 20519718
[TBL] [Abstract][Full Text] [Related]
34. A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy.
Gürtler N; Plasilova M; Podvinec M; Boesch N; Müller H; Heinimann K
Laryngoscope; 2006 Jan; 116(1):111-4. PubMed ID: 16481821
[TBL] [Abstract][Full Text] [Related]
35. Over-expression of BCL2 rescues muscle weakness in a mouse model of oculopharyngeal muscular dystrophy.
Davies JE; Rubinsztein DC
Hum Mol Genet; 2011 Mar; 20(6):1154-63. PubMed ID: 21199860
[TBL] [Abstract][Full Text] [Related]
36. PABPN1 gene therapy for oculopharyngeal muscular dystrophy.
Malerba A; Klein P; Bachtarzi H; Jarmin SA; Cordova G; Ferry A; Strings V; Espinoza MP; Mamchaoui K; Blumen SC; St Guily JL; Mouly V; Graham M; Butler-Browne G; Suhy DA; Trollet C; Dickson G
Nat Commun; 2017 Mar; 8():14848. PubMed ID: 28361972
[TBL] [Abstract][Full Text] [Related]
37. Oculopharyngeal muscular dystrophy among Bulgarian Jews: a new cluster?
Blumen SC; Kesler A; Dabby R; Shalev S; Khayat M; Almog Y; Zoldan J; Benninger F; Drory VE; Gurevich M; Sadeh M; Brais B; Braverman I
Isr Med Assoc J; 2013 Dec; 15(12):748-52. PubMed ID: 24449978
[TBL] [Abstract][Full Text] [Related]
38. Continuous remodeling of adult extraocular muscles as an explanation for selective craniofacial vulnerability in oculopharyngeal muscular dystrophy.
Wirtschafter JD; Ferrington DA; McLoon LK
J Neuroophthalmol; 2004 Mar; 24(1):62-7. PubMed ID: 15206442
[TBL] [Abstract][Full Text] [Related]
39. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene.
van der Sluijs BM; van Engelen BG; Hoefsloot LH
Hum Mutat; 2003 May; 21(5):553. PubMed ID: 12673802
[TBL] [Abstract][Full Text] [Related]
40. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells.
Wang Q; Mosser DD; Bag J
Hum Mol Genet; 2005 Dec; 14(23):3673-84. PubMed ID: 16239242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
